EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates

Mengqing Zhao, Yan Deng, Jianjian Han, Yong Xie, Kai Bao, Lixin Ma, Lilong Liu, Wuxiang Mao iD

Advanced Science · 2026-08 · 13 (44)

DOI: 10.1002/advs.75658 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 15.05.2026. Verfasst von Mengqing Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biocatalysis and Enzyme Engineering, Hubei Province Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hube…. Hauptthemen laut MEDLINE: Proteolysis, Antineoplastic Agents. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development (R&D) Program of China, National Natural Science Foundation of China, the Project of Technological Innovation Plan in Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditional targeted protein degradation (TPD) strategies are largely ineffective against membrane proteins, which constitute over 60% of drug targets. To address this, we develop a modular “plug‐and‐play” UPTAB (Ultrahigh‐affinity Protein pairs fused to Targeting Binders) platform for TPD. The platform leverages orthogonal ultrahigh‐affinity Im/CL protein pairs to assemble complexes between lysosomal trafficking receptor (LTR)‐binding modules and protein of interest (POI)‐binding modules. Three UPTAB configurations were engineered: Type‐I (mono‐targeted), Type‐II (dual‐targeted), and Type‐III (tri‐targeted). In vitro, Type‐I UPTAB achieved near‐complete degradation of EGFR and PD‐L1 across multiple cancer cell lines, with optimal linker length critical for maximal activity. Type‐II and Type‐III UPTAB enabled simultaneous degradation of EGFR/c‐MET, EGFR/PD‐L1, and EGFR/c‐MET/HER2. In a breast cancer xenograft model, Type‐I UPTAB demonstrated approximately 80% tumor growth inhibition, reduced EGFR levels in tumors, and significantly extended survival. Furthermore, we developed degrader‐drug conjugates (DDCs) by site‐specific conjugation of the cytotoxic payload MMAE to UPTAB modules, which retained degradation capacity while exhibiting substantially enhanced anti‐proliferative activity across diverse cancer cell lines. The UPTAB platform combines modular multivalent design, high degradation efficiency, and excellent bioconjugation capability, offering a versatile tool for membrane protein‐targeted degradation and a potential strategy for developing next‐generation cancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteolysisAntineoplastic AgentsHumansAnimalsMiceCell Line, TumorProteolysis Targeting ChimeraErbB ReceptorsFemale

Stichwörter der Autor:innen

LYTACdegrader‐drug conjugatesmultivalencyplug‐and‐playprotein pairs

Substanzen

Proteolysis Targeting ChimeraErbB ReceptorsAntineoplastic Agents

Autor:innen und Institutionen

  • State Key Laboratory of Biocatalysis and Enzyme Engineering, Hubei Province Key Laboratory of Industrial Biotechnology, School of Life Sciences, Hubei University, Wuhan, China.
  • Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID-Profile: Wuxiang Mao

Förderung

  • National Key Research and Development (R&D) Program of China
  • National Natural Science Foundation of China
  • the Project of Technological Innovation Plan in Hubei Province
  • Natural Science Foundation
  • the Natural Science Foundation of Wuhan City

Zitieren

APA

Zhao, M., Deng, Y., Han, J., Xie, Y., Bao, K., Ma, L., Liu, L., & Mao, W. (2026). A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates. Advanced Science, 13(44). https://doi.org/10.1002/advs.75658

Vancouver

Zhao M, Deng Y, Han J, Xie Y, Bao K, Ma L, et al. A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates. Advanced Science. 2026;13(44). doi:10.1002/advs.75658

BibTeX
@article{Zhao2026,
  author = {Zhao, Mengqing and Deng, Yan and Han, Jianjian and Xie, Yong and Bao, Kai and Ma, Lixin and Liu, Lilong and Mao, Wuxiang},
  title = {A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {44},
  doi = {10.1002/advs.75658}
}
Kostenlos starten →